[Temporary Announcement] Fukang Pharmaceutical: Announcement of Resolutions of the Ninth Meeting of the Fourth Board of Supervisors
Announcement number: 2026-008
Securities code: 831838 Securities abbreviation: Fukang Pharmaceutical Sponsored securities firm: Cathay Haitong
Jilin Fukang Pharmaceutical Co., Ltd.
Announcement of Resolutions of the Ninth Meeting of the Fourth Supervisory Board
The Company and all members of the Supervisory Board guarantee that the contents of the announcement are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability for the authenticity, accuracy and completeness of the contents.
1. Meeting convening and attendance
(1) Meeting status
- Meeting time: April 22, 2026
2.Meeting method: √On-site meeting □Electronic communication meeting
Meeting location: Company Conference Room, No. 3, Huarui Road, Dunhua Economic Development Zone, Jilin Province
Time and method of issuing notice of meeting of the Supervisory Board: April 12, 2026 in writing 5. Meeting host: Zhang Weichen
Explanation on the legality and compliance of the convening situation:
The convening and holding procedures of this meeting complied with the provisions of the "Company Law of the People's Republic of China", "Articles of Association" and relevant regulations and laws.
(2) Meeting attendance
The meeting should be attended by 3 supervisors, and 3 supervisors should be present and authorized to attend the meeting.
2. Proposal review status
(1) Consideration and approval of the "Proposal on the Work Report of the Supervisory Board of Jilin Fukang Pharmaceutical Co., Ltd. for 2025"
- Contents of the motion:
Contents related to the work of the Board of Supervisors in 2025.
- Refusal to vote
Announcement number: 2026-008
This motion does not involve related matters and there is no need to avoid voting.
Voting results of the motion: 3 votes in favor; 0 votes against; 0 abstentions.
Submit the voting status of the shareholders’ meeting:
This proposal still needs to be submitted to the shareholders' meeting for review.
(2) Review and adoption of the "About Review of the 2025 Annual Report of Jilin Fukang Pharmaceutical Co., Ltd. and its Summary"
Proposal to be >
- Contents of the motion:
For details of the "Jilin Fukang Pharmaceutical Co., Ltd. 2025 Annual Report and its Summary", please refer to the "Jilin Fukang Pharmaceutical Co., Ltd. 2025 Annual Report" (Announcement No.: 2026-009) and "Jilin Fukang Pharmaceutical Co., Ltd. 2025 Annual Report Summary" (Announcement No.: 2026-010) published on the National Small and Medium Enterprises Exchange Information Disclosure Platform (www.neeq.com.cn).
- Refusal to vote
This motion does not involve related matters and there is no need to avoid voting.
Voting results of the motion: 3 votes in favor; 0 votes against; 0 abstentions.
Submit the voting status of the shareholders’ meeting:
This proposal still needs to be submitted to the shareholders' meeting for review.
(3) Deliberation and approval of the "About the Deliberation of the 2025 Financial Final Accounts Report of Jilin Fukang Pharmaceutical Co., Ltd."
motion"
- Contents of the motion:
Contents of the 2025 financial accounts.
- Refusal to vote
This motion does not involve related matters and there is no need to avoid voting.
Voting results of the motion: 3 votes in favor; 0 votes against; 0 abstentions.
Submit the voting status of the shareholders’ meeting:
This proposal still needs to be submitted to the shareholders' meeting for review.
Announcement number: 2026-008
(4) Deliberation and approval of the "About the Deliberation of the 2026 Financial Budget Report of Jilin Fukang Pharmaceutical Co., Ltd."
motion"
- Contents of the motion:
Contents of the 2026 financial budget.
- Refusal to vote
This motion does not involve related matters and there is no need to avoid voting.
Voting results of the motion: 3 votes in favor; 0 votes against; 0 abstentions.
Submit the voting status of the shareholders’ meeting:
This proposal still needs to be submitted to the shareholders' meeting for review.
(5) Deliberation and approval of the "About the Review of Jilin Fukang Pharmaceutical Co., Ltd.'s 2025 Annual Profit Distribution Plan"
Proposal>Proposal>
- Contents of the motion:
After comprehensively considering the actual operating conditions in 2025, its own profitability, business development plan, future capital chain and other factors, the equity distribution plan for 2025 is determined as follows:
According to the Zhongxing Huashen Zi (2026) No. 00007103 audit report issued by Zhongxing Hua Accounting Firm (Special General Partnership) on April 22, 2026, the company's cumulative undistributed profit as of December 31, 2025 was 13291176.65 yuan. After deliberation at the 13th meeting of the company's fourth board of directors held on April 22, 2026, based on the company's existing total share capital of 15,220,000 shares, a cash dividend of 5 yuan (including tax) will be distributed to shareholders participating in the distribution based on undistributed profits for every 10 shares. A total of RMB 7,610,000 in cash dividends is expected to be distributed in this equity distribution. If the number of shares to be distributed on the equity registration date is inconsistent with the number of shares to be distributed in the equity distribution plan, the company will maintain the total distribution amount unchanged and adjust the distribution ratio accordingly. An announcement will be issued later to explain the adjusted distribution ratio. The actual distribution results are subject to the calculation results of China Securities Depository and Clearing Co., Ltd.
The personal income taxes involved in the above-mentioned equity distribution shall be implemented in accordance with the "Announcement on the Continued Implementation of the Differentiated Personal Income Tax Policy on Dividends and Bonuses of Companies Listed on the National Small and Medium-sized Enterprise Share Transfer System" (Ministry of Finance, State Administration of Taxation, and China Securities Regulatory Commission Announcement No. 78 of 2019).
After this profit distribution, the undistributed profits will be carried forward and distributed in subsequent years.
Announcement number: 2026-008
- Refusal to vote
This motion does not involve related matters and there is no need to avoid voting.
Voting results of the motion: 3 votes in favor; 0 votes against; 0 abstentions.
Submit the voting status of the shareholders’ meeting:
This proposal still needs to be submitted to the shareholders' meeting for review.
(6) Review and adoption of the "About Review of the Controlling Shareholders and Other Related Parties of Jilin Fukang Pharmaceutical Co., Ltd."
Special Explanation of Fund Occupation>Proposal》
- Contents of the motion:
Zhongxinghua Baozi (2026) No. 00000417 "Special Explanation on the Occupation of Funds by the Controlling Shareholders and Other Related Parties of Jilin Fukang Pharmaceutical Co., Ltd." issued by Zhongxinghua Accounting Firm (Special General Partnership).
- Refusal to vote
This motion does not involve related matters and there is no need to avoid voting.
Voting results of the motion: 3 votes in favor; 0 votes against; 0 abstentions.
Submit the voting status of the shareholders’ meeting:
This proposal does not need to be submitted to the shareholders' meeting for review.
3. Documents for reference
"Resolution of the Ninth Meeting of the Fourth Supervisory Board of Jilin Fukang Pharmaceutical Co., Ltd."
Jilin Fukang Pharmaceutical Co., Ltd. Supervisory Board
April 24, 2026